Monitor on Psychology , 56 (5)
Yes, though the transition requires starting retatrutide at 1 mg regardless of your previous dose
If GLP-1 agonists pose a similar risk, thats important to knowand if they dont, it could further accelerate the sea change occurring in our approach to treating obesity. The studys results, published in JAMA Psychiatry , suggest that the similarities in outcome between the two approaches do not include that potential downside
u003ca href=u0022#Safety-Strategy-and-Next-Stepsu0022u003eGLP-1 injections are not typically bad for youu003c/au003e
AOM, anti-obesity medication
The package arrives in temperature-controlled packaging with ice packs to maintain medication integrity, which matters significantly for peptide stability